Cargando…

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease

Early identification of Alzheimer’s disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A...

Descripción completa

Detalles Bibliográficos
Autores principales: Janel, N, Alexopoulos, P, Badel, A, Lamari, F, Camproux, A C, Lagarde, J, Simon, S, Feraudet-Tarisse, C, Lamourette, P, Arbones, M, Paul, J L, Dubois, B, Potier, M C, Sarazin, M, Delabar, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537644/
https://www.ncbi.nlm.nih.gov/pubmed/28632203
http://dx.doi.org/10.1038/tp.2017.123
_version_ 1783254220053413888
author Janel, N
Alexopoulos, P
Badel, A
Lamari, F
Camproux, A C
Lagarde, J
Simon, S
Feraudet-Tarisse, C
Lamourette, P
Arbones, M
Paul, J L
Dubois, B
Potier, M C
Sarazin, M
Delabar, J M
author_facet Janel, N
Alexopoulos, P
Badel, A
Lamari, F
Camproux, A C
Lagarde, J
Simon, S
Feraudet-Tarisse, C
Lamourette, P
Arbones, M
Paul, J L
Dubois, B
Potier, M C
Sarazin, M
Delabar, J M
author_sort Janel, N
collection PubMed
description Early identification of Alzheimer’s disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related markers brain-derived neurotrophic factor (BDNF) and homocysteine in two unrelated AD patient cohorts with age-matched controls. Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers. These results associate a decreased level of DYRK1A with AD and challenge the use of DYRK1A inhibitors in peripheral tissues as treatment. These measures will be useful for diagnosis purposes.
format Online
Article
Text
id pubmed-5537644
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55376442017-08-02 Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease Janel, N Alexopoulos, P Badel, A Lamari, F Camproux, A C Lagarde, J Simon, S Feraudet-Tarisse, C Lamourette, P Arbones, M Paul, J L Dubois, B Potier, M C Sarazin, M Delabar, J M Transl Psychiatry Original Article Early identification of Alzheimer’s disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related markers brain-derived neurotrophic factor (BDNF) and homocysteine in two unrelated AD patient cohorts with age-matched controls. Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers. These results associate a decreased level of DYRK1A with AD and challenge the use of DYRK1A inhibitors in peripheral tissues as treatment. These measures will be useful for diagnosis purposes. Nature Publishing Group 2017-06 2017-06-20 /pmc/articles/PMC5537644/ /pubmed/28632203 http://dx.doi.org/10.1038/tp.2017.123 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Article
Janel, N
Alexopoulos, P
Badel, A
Lamari, F
Camproux, A C
Lagarde, J
Simon, S
Feraudet-Tarisse, C
Lamourette, P
Arbones, M
Paul, J L
Dubois, B
Potier, M C
Sarazin, M
Delabar, J M
Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
title Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
title_full Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
title_fullStr Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
title_full_unstemmed Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
title_short Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
title_sort combined assessment of dyrk1a, bdnf and homocysteine levels as diagnostic marker for alzheimer’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537644/
https://www.ncbi.nlm.nih.gov/pubmed/28632203
http://dx.doi.org/10.1038/tp.2017.123
work_keys_str_mv AT janeln combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT alexopoulosp combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT badela combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT lamarif combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT camprouxac combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT lagardej combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT simons combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT feraudettarissec combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT lamourettep combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT arbonesm combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT pauljl combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT duboisb combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT potiermc combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT sarazinm combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease
AT delabarjm combinedassessmentofdyrk1abdnfandhomocysteinelevelsasdiagnosticmarkerforalzheimersdisease